Abstract
Background: Diabetes mellitus imposes a substantial health and economic cost on societies. Novel antidiabetic medicines are necessary because the present therapies have impoverished safety and effectiveness. Traditional medicines often make use of medicinal plants, which are considered to be excellent choices. Objective: The aim of the research to investigating the potential anti-diabetic activities of extracts from Litchi chinensis seeds (LCS). Methods: The extract was prepared using an aqueous solvent and 80% ethanol. It was subsequently used in laboratory settings to investigate primary alpha amylase inhibition, with acarbose serving as the reference standard. The extract was then administered in vivo to observe the effects on STZ-mediated diabetes rats. The induction of diabetes in Long-Evans rats was achieved by administering a solitary intraperitoneal injection of streptozotocin at a dosage of 80 mg/kg. the hydroethanolic extract of litchi seed were used at different concentrations (100 and 200 mg/kg BW) to treat rats with diabetes. The finding analyzed various biochemical and histological parameters in diabetic rats over a period of 28 day, using established protocols. Results: The results showed significant improvements in plasma glucose (p < 0.001) and considerable increased in body weight (p < 0.0001). The LCS extract (200 mg/kg BW) showed significant ameliorative effects on glycemic markers, lipid profile, and renal functioning. Additionally, histopathological studies reveals that LCS can potentially reduce renal inflammation as well as hepatic tissue damage. Conclusions: The findings indicate that hydroethanolic litchi seed extracts may have potential therapeutic benefits in managing diabetes and reducing lipid levels.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call